Greetings. It is my privilege to introduce the section
With the report of Irons and colleagues (3) the theme shifts to stem cells, in particular bone marrow stromal of this issue of Cell Transplantation devoted to the 10th annual meeting of the American Society for Neural cells, and their engraftment in a rat model of stroke. This study highlights the fascinating interactions between Transplantation and Repair (ASNTR), which was held May 1-4, 2003. The reports, commentary, and review transplanted cells and the cues expressed by the injured adult brain. pieces that follow are an accurate capsule review of the meeting. The Society has many attributes that can be Second, the ASNTR meeting is an open forum for debate of issues in the field of central nervous system pointed to with justifiable pride. Two of these were in clear evidence at the 2003 meeting, and are represented repair. One debate that likely will continue for years is the therapeutic use of stem cells.
Yurek and Fletcher-in the pages that follow.
First, ASNTR has a long history of encouraging the Turner (6) begin to wrestle with the emerging differences between a neuron instructed to be dopaminergic participation of young investigators and enabling that participation by providing student travel awards for the by nature (primary embryonic dopamine neurons) and those pushed to that phenotype by us (stem cells "con-meeting. In recent years, ASNTR has provided no fewer than 10 travel awards for each meeting. The generosity verted" to the dopamine phenotype). The review by Ourednik and Ourednik (5) crystallizes a concept less and support of the sponsors of these awards is duly noted, and we have them to thank for the impact these appreciated in stem cell biology: that stem cells can instruct the mature injured brain to recapitulate the plastic-young scientists have on the meeting. In return, the ASNTR meeting often becomes the first national confer-ity of immaturity to serve the goal of brain repair. Finally, a highlight of the 2003 ASNTR meeting was the ence at which these investigators present their studies. The determined absence of concurrent scientific sessions session and open forum discussing current events in clinical trials for neural transplantation as a therapy for ensures that they have an attentive and engaged audience. Three of the reports in this issue are authored by Parkinson's disease. One investigator involved in this journey since the beginning is Dr. William Freed, and ASNTR student travel award winners. Reports by Alemdar and colleagues and Marchionini and colleagues he has graciously translated his comments in that forum to a commentary piece on the past, present, and future are directed at the optimization of survival and integration of embryonic dopamine neuron grafts in the rat of neural transplantation (2). I am grateful to all those who made this special sec-model of Parkinson's disease. Less than optimal survival and integration of grafted cells remains a significant tion of the journal possible: the authors, my colleagues enlisted to review the submissions (often on short no-problem for the therapeutic application of cell replacement therapies in many systems. Alemdar et al. (1) de-tice), the editors and publishers of Cell Transplantation. Enjoy. scribe the delivery of liposomal formulations of neuroimmunophilins in conjunction with embryonic dopamine neurons as one way to enhance therapeutic outcome. Their results also suggest that different immunophilins REFERENCES have different effects on reinnervation and may effec- and this report suggests that efficacy may be related to 319-327; 2004. the specific formulation of cultures and grafts and may 
